353 Continuous IV infusion of vinorelbine (VNB) and bolus cisplatinum (CDDP) (civic regimen) an efficient regimen in hormono resistant metastatic breast cancer (MBC), after failure of antracycline and/or paclitaxel

We have investigated a new chemotherapy regimen (CT) in patients (pts) previously treated with CT and/or hormonotherapy. CDDP of 20 mg/m 2 /day was given, (Dl to D5) every 21 days in 1 H iv infusion and VNB was given with the dose of 6 mg IVD bolus, followed by VNB 6 mg/ 2 /day in continuous iv infusion (Dl to D5) every 21 days. 59 pts were included in this trial (median age: 46 years, range 28–49; premenopausal: 40 pts). Respectively 44 and 12 pts had previously anthracyclines (adm) and paclitaxel containing regimens. Overall 212 courses were given (median 3, range 1–6): myelosuppression was the most frequent side effect: neutropenia WHO grade III occurred in 41 courses (20%) on 212 and grade IV for 64 courses (31%). Thrombopenia WHO grade III and IV for 23 courses (12%). No cumulative toxicity was observed on bone marrow. Grade II peripheric neuropathy was observed in 12 of 212 courses (6%) and grade III in 4 of 212 courses (2%) with correlation between toxicity and numbers of courses. Neuropathy (grades II and III) occurred most often after 4 courses (CHI 2: 30.2; P CIVIC is an effective and well tolerated regimen in MBC resistant to previous anthracylines and/or paclitaxel containing CT. A number of 4 courses seems to give the best toxicity-efficacy ratio. Partly sponsored par grant PHRC 94 of the French Ministry of Health.